Avadel Pharmaceuticals (AVDL) Operating Income: 2009-2021
Historic Operating Income for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$85.5 million.
- Avadel Pharmaceuticals' Operating Income fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Operating Income of -$85.5 million as of FY2021, which was down 1,571.13% from $5.8 million recorded in FY2020.
- Avadel Pharmaceuticals' 5-year Operating Income high stood at $89.5 million for FY2017, and its period low was -$104.9 million during FY2018.
- Moreover, its 3-year median value for Operating Income was -$24.1 million (2019), whereas its average is -$34.6 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Operating Income surged by 1,902.72% in 2017 and then plummeted by 1,571.13% in 2021.
- Yearly analysis of 5 years shows Avadel Pharmaceuticals' Operating Income stood at $89.5 million in 2017, then slumped by 217.23% to -$104.9 million in 2018, then soared by 77.02% to -$24.1 million in 2019, then spiked by 124.12% to $5.8 million in 2020, then plummeted by 1,571.13% to -$85.5 million in 2021.